Kinetics of vibriocidal antibody responses among cholera patients in Goma, the Democratic Republic of Congo

Kilee L. Davis*[1], Carmen Nieznanski*[1], Felicien Maisha[2], Ben J. Brintz[3], Christy Clutter[1], Meer Alam[4], Cyrus Saleem[4], Afsar Ali[4], J. Glenn Morris[4], Daniel T. Leung[1]

*co-first author

[1] Division of Infectious Disease, Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA

[2] Department of Sociology, college of humanity and social sciences, University of Goma. Democratic Republic of Congo

[3] Division of Epidemiology, Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA

[4] Emerging Pathogens Institute, University of Florida, Gainesville, Florida, USA

Corresponding author:

Daniel T. Leung, MD,

Division of Infectious Disease,

30 N Mario Capecchi Dr,

Salt Lake City, Utah, 84112, USA.

Email: daniel.leung@utah.edu

Abstract

Cholera is a diarrheal disease that continues to burden vulnerable populations globally, primarily due to lack of clean water, optimal sanitation and adequate health infrastructure. Understanding the kinetics of antibody responses elicited by toxigenic *Vibrio cholerae* infection can inform the Sero-epidemiological estimation of disease burden and impact of vaccination efforts. While antibody kinetics have been well-described in South Asia, such studies based in Africa are lacking, despite the ongoing prevalence of cholera in that region. We enrolled stool culture-positive cholera patients admitted to cholera treatment centers in Goma, Democratic Republic of Congo (DRC) between August 2020 and October 2023. Blood samples were collected upon enrollment and during follow-up home visits. We performed vibriocidal assays against *V. cholerae* O1 Inaba and Ogawa on 212 serum samples from 116 patients, 101 of whom had serotype information available (53% Male; 62% Female, Median age 8 (IQR 4-18). Vibriocidal antibody responses peaked between day 7 and 40 post symptom onset and then waned, with nearly all samples declining to a titer of 320 or lower by day 90, and 160 or lower by day 180. We used a Bayesian exponential decay model to show that there is an approximately 88% probability of a slower decay in participants over 5 years of age compared to younger aged subjects. Our findings corroborate the findings of prior studies conducted in hyperendemic areas in South Asia and provide critical data to inform the timing of vaccination campaigns and interpretation of serosurveillance results in African populations.

Introduction

Cholera is an acutely dehydrating diarrheal disease caused by the aquatic Gram-negative toxigenic bacterium *Vibrio cholerae* [1]. *V. cholerae* is transmitted via the ingestion of contaminated food and/or water making it most prevalent in poverty-afflicted communities around the world where water and sanitation infrastructure is limited [2]. Cholera disease surveillance can be challenging due to limited capacity for disease surveillance in places where the disease occurs, variations in its seasonality, and the non-specificity of cholera symptoms [3] Additionally, laboratory confirmation has a limited impact on treatment and is infrequently performed. An emerging method for estimating cholera burden is Sero-surveillance, involving measurement of cholera-specific antibody in blood obtained from a representative cross-sectional sampling of a defined population. Aside from burden estimates, Sero-surveillance can also be potentially used to estimate a population's immunity level. Such knowledge can inform public health strategies, including the timing of deployment of interventions such as vaccination.

Longitudinal studies examining kinetics of antibody responses to cholera are crucial for interpreting cross-sectional Sero-surveillance data. Until now, kinetics of cholera antibody response have been mostly limited to patients with severe cholera in Bangladesh (a hyper-endemic region) [4]. There is a paucity of data on the kinetics of antibody responses against cholera in endemic regions outside of South Asia. Our primary aim is to investigate the long-term kinetics of *V. cholerae* antibody responses among patients in Goma, DRC, a cholera-endemic region in Africa. Our secondary aim is to compare the antibody kinetics between young children and older persons.

Methods

Patient recruitment and collection of samples

To examine longitudinal antibody response elicited by *V. cholerae* infection, we measured vibriocidal antibody titers of patients with culture-confirmed *V. cholerae* O1 infections. Study participants were recruited from patients with watery diarrhea who presented to cholera treatment centers operated by the Health Division of the Province of North Kivu in Goma, DRC from August 2020 to October 2023. Written informed consent was obtained from participants or their parents/guardians for those aged 17 and younger, with assent from participants aged 7 and older. Following informed consent, clinical and epidemiological data were collected into REDCap (Research Electronic Data Capture, [5]) through the University of Florida Clinical and Translational Science Institute. This study was approved by the IRB of the University of Florida and the Comité Éthique de l'Université Libre des Pays des Grands Lacs.

Stool and venous blood samples were collected at enrollment. Stool cultures were performed to detect *V. cholerae* O1. Serum was separated and stored at -80°C for future analysis. Two follow-up visits were attempted to collect venous blood samples at approximately 4 weeks and 6 months post-enrollment. Time points were used to generally describe serum samples' collection while the exact day since symptom onset was used in our analysis. The last recorded blood sample was collected in February 2024.

Vibriocidal Assay

Vibriocidal antibodies are the best correlation of protection against cholera [14], and the best marker for prior infection [4]. We performed the vibriocidal assay for *V. cholerae* O1 Inaba and

88 Ogawa serotype as previously described [6] Positive control, an IgG monoclonal antibody
89 against V. cholerae O1 O-specific polysaccharide (gift of Dr. Jason Harris, Massachusetts
90 General Hospital, Boston MA), was added to naïve serum at 6.24 μg/μL corresponding to a
91 vibriocidal titer of 640. Heat-inactivated serum samples were duplicated, then serially diluted
92 two-fold in saline from 1:10 to 1:10,240 in a 96-well microplate. Negative control (bacteria
93 without serum) and positive control were included on each plate. V. cholerae O1 Ogawa and
94 Inaba strains were grown in Luria Broth (LB) at 37°C for 3 hours, washed with saline, then
95 resuspended to an optical density (OD) of 0.3 at 600nm. A Growth Indicating Solution was
96 prepared with guinea pig complement (Sigma) diluted 1:10 and the bacterial suspension diluted
97 1:20 in saline. This solution was added to the samples and positive control wells. Plates were
98 incubated at 37ºC at 50 rpm for 1 hour, then LB was added and incubated at 37ºC without
99 shaking for 2 hours. Plates were measured when the growth indicator reached OD600 of at least
100 0.2. Vibriocidal titers were defined as the reciprocal of the highest serum dilution resulting in
101 approximately 50% of the mean OD600 of the Growth Control wells. Samples below the
102 detection limit were assigned a titer of 5, and those above the limit were assigned a titer of
103 20,480.

104 Statistical Analysis

105 We examined the kinetics of vibriocidal titers over time, using the titer of the serotype matched
106 by culture results. We used the ggplot2 package in R (R version 4.4.1.[7]) for data visualization.
107 Given the paucity of data on the long-term kinetics of cholera antibody responses in children
108 under 5, we used vibriocidal titers from participants which had at least 2 paired samples to fit a
109 Bayesian model using the cmdstanr package in R to estimate exponential decay parameters
110 describing the amplitude of titers and the rate of decay. The model assumes the observed and

logged titer values follow a normal distribution with mean $N_{0(i)} * e^{-(k1+over_i*k2)}$ and variance σ where $N_{0(i)}$ is the person-specific amplitude, $k1$ is the decay rate for the under-5 group, $over_i$ is an indicator variable for being over-5, and $k2$ is the change in decay rate for the over-5 group. Given that in preliminary analyses, the majority of patients' initial vibriocidal titer was their highest titer, we assumed that we missed the initial rise in titer value to the amplitude and thus our model equation doesn't include the rise in titer value and only examined the rate of decay. Correspondingly, we also excluded any subjects' titers if they had a titer value of 5 (below limit of detection) between 3 and 60 days of follow-up or those who never mounted a detectable antibody response. We use uninformative priors (see supplement for full stan model).

Results

We performed vibriocidal assays on serum from 212 samples from 116 culture-confirmed *V. cholerae* patients (53% Male; Median age 8 (IQR 4-18)). Of the 101 participants for which serotype information was available, 83 (82%) of participants were infected with Ogawa serotype, 15 (15%) with Inaba, and 3 (3%) with Hikojima. Children under 5 represented 37% of the participants and 27 (25%) participants self-reported prior oral cholera vaccination. Among all participants, 20 (20%) had serum samples from three time points, 57 (56%) had 2 timepoints and 38 (38%) participants only one time point. Sample collection from many households was delayed due to unanticipated problems in reaching patient homes for repeat visits and, in some instances, restrictions on travel related to safety concerns. Because of this, there was substantial variability in the time of collection of what were initially scheduled as four week and six-month post-infection visits. Consequently, data were recorded and analyzed as number of days between the onset of illness and the date of sample collection, with second samples collected between 3 to 297 days, and third samples collected between 25 to 449 days after symptom onset (Fig. 1).

Overall, the highest vibriocidal responses were noted between 7 and 40 days and waned over time, with nearly all waning to a titer of 320 or lower by 90 days, and to a titer of 160 or lower by 180 days (Figure 1). We then used data from all participants which had at least 2 paired samples to examine differences in decay kinetics between participants 5 years of age and younger compared with those over 5 (Figure 2). In the exponential decay model, we found a negative posterior mean for k_2, the parameter indicating a change in decay for the participants over 5, with 95% posterior credible intervals overlapping 0 (k_2: -0.0012 (-0.0030, 0.0004). The draws from the posterior distribution of k_2 suggest there is an approximately 88% probability of

a slower decay in participants over 5 (Figure 2). Given that prior vaccination may increase the probability of a slower decay, we did a sensitivity analysis among those without prior vaccination and found similar results (k_2: -0.0014 (-0.0041, 0.0007), with an approximately 83% probability of a slower decay in participants over 5).



Figure 1: Post-infection vibriocidal titer responses from confirmed cholera cases. Vibriocidal titers by matching *V. cholerae* O1 serotype from 101 participants, by (A) serotype, and (B) age group. Days since symptom onset on the x-axis, and vibriocidal titer on the y-axis,

151 are plotted on log2-transformed scales. Hashed lines are LOESS smoothed data with confidence

152 intervals in shade.



Figure 2. Estimated vibriocidal titer decay rates between age groups. Estimated average titer value and 95% posterior credible interval for serotype-matched vibriocidal titers from the exponential decay equation plotted against days since symptom onset, by participants over 5 years of age (left) and under 5 (right). Each line represents the vibriocidal titer decay of a participant with at least 2 paired samples, fitted to a Bayesian model to estimate exponential decay parameters describing the amplitude of titers and the rate of decay.

Discussion

In this longitudinal study of culture-confirmed cholera patients in Goma, DRC, we describe the vibriocidal antibody kinetics of patients from a cholera-endemic area in Africa, for up to one year post symptom onset. We show that vibriocidal antibody responses from children under 5 likely wanes more rapidly than those in older children and adults, and that both groups had few with titers above 160 at one-year post-infection. These data suggest that young children may be more vulnerable to repeat infection than adults, though both groups may require vaccination to boost immunity.

We found that the vibriocidal antibody response decays over time, results consistent with previous studies performed on South Asian populations with medically attended cholera cases [8]. Due to differences in laboratories, assay controls, and sampling approach, we are unable to make statistical comparisons between ours with previous studies. Nevertheless, factors that may contribute to differences in kinetics between populations from different geographic regions, including degree of "endemicity", proportion with prior vaccination, and age distribution.

Aside from geographic differences, the predominance of young children in our study is unique compared to prior studies of vibriocidal kinetics, which have featured mostly older children and adults. Leveraging this, and the longitudinal nature of the study, we show that the waning of the vibriocidal response in young children (age 5 and lower) is likely faster than that of older persons. While the 95% posterior credible interval contains 0, a null result in the frequentist sense, our Bayesian model estimates a high probability that there is a differing decay rate between age groups. This finding fills a knowledge gap, suggesting that interventions such as

185 the use of vaccination to boost immune response, may benefit even those in this age group who
186 had a recent infection.
187
188 Oral cholera vaccine (OCV) campaigns can effectively increase immunity through both
189 individual and herd-based immunity in high-risk areas, but the duration depends critically on
190 population drivers such as vaccine coverage, waning vaccine efficacy, and net influx of
191 susceptible people through population mobility [9]. Indeed, preventive OCV campaigns
192 conducted in the study area in the years prior to the study period showed that absence and
193 unawareness were the main reasons for non-vaccination [10]. Furthermore, our recent qualitative
194 work on the social dynamics influencing cholera risk in this area identified community
195 skepticism regarding efficacy of recent vaccination campaigns, and misinformation about the
196 vaccine's supposed dangers and side effects, which may have discouraged individuals
197 vaccination uptake. While longitudinal serological data could help guide the timing of future
198 vaccination campaigns, it is crucial to address the sociological factors that may contribute to
199 distrust of the cholera vaccine and the humanitarian infrastructures responsible for its distribution
200 among at-risk communities in Goma.
201
202 Our study had several limitations. Study participants were limited to individuals who could
203 access cholera treatment centers. We observed a variance in collection timepoint dates as our
204 field study team faced difficulties revisiting households within the 4 weeks to 6-month follow-up
205 periods. Due to low sample size, our study was not powered to evaluate the difference in
206 antibody response among vaccinated and unvaccinated individuals. Although the vibriocidal
207 antibody response is the best non-mechanistic correlate of protection against *V. cholerae* [4][11],

208 the vibriocidal titer alone has not demonstrated to be completely predictive of long-term
209 immunity against clinical disease.
210
211 Nevertheless, we present the post-infection vibriocidal kinetics of a large cohort of culture-
212 confirmed cholera patients in an endemic region of Africa and show evidence that children under
213 5 may have a faster decay rate than older persons. Our study begins to address the data gap in
214 longitudinal antibody response studies outside of South Asia and suggests that more frequent
215 boosting with vaccine may be needed for cholera-vulnerable communities like those in Goma,
216 DRC.
217
218 ***Author contributions.*** *A.A., J.G.M., and D.T.L.* conceived and planned the experiments and
219 acquired funding for the study. F.M. and M.A. recruited and enrolled patients and collected
220 samples for the study. K.L.D. and C.N. carried out the laboratory assays. K.L.D., C.N., B.J.B.
221 C.C., and C.S. performed data management and statistical analysis. K.L.D., C.N., and D.T.L.
222 wrote the first draft of the manuscript. All authors reviewed and edited the manuscript.
223
224 ***Acknowledgements:*** We acknowledge the contributions of DRC National Program for the
225 Elimination of Cholera and Other Diarrheal Diseases (PNECHOL- DM); The North Kivu
226 Provincial Health Division (DPS-NK); Appui Medical Integre aux Activites de Laboratoire
227 (AMI-LABO); HEAL Africa.
228
229 ***Financial support.*** This study was supported in part by awards from the National Institutes of
230 Health (R01AI135115 to DTL; R01AI138554 to JGM), the University of Utah Undergraduate

Research Opportunities Program (to CN), and the Dr. Thomas D. Rees and Natalie B. Rees Presidential Endowed Chair in Global Medicine (to DTL)

Potential conflicts of interest. None.

Supplementary Materials

238 **References**

239 [1] S. Kanungo, A. S. Azman, T. Ramamurthy, J. Deen, and S. Dutta, "Cholera," 2022. doi:
240 10.1016/S0140-6736(22)00330-0.

241 [2] World Health Organization, "Cholera. https://www.who.int/news- room/fact-
242 sheets/detail/cholera," WHO.

243 [3] A. S. Azman, S. M. Moore, and J. Lessler, "Surveillance and the global fight against
244 cholera: Setting priorities and tracking progress," 2020. doi:
245 10.1016/j.vaccine.2019.06.037.

246 [4] A. S. Azman *et al.*, "Estimating cholera incidence with cross-sectional serology," *Sci*
247 *Transl Med*, vol. 11, no. 480, 2019, doi: 10.1126/SCITRANSLMED.AAU6242.

248 [5] P. A. Harris, R. Taylor, R. Thielke, J. Payne, N. Gonzalez, and J. G. Conde, "Research
249 electronic data capture (REDCap)-A metadata-driven methodology and workflow process
250 for providing translational research informatics support," *J Biomed Inform*, vol. 42, no. 2,
251 2009, doi: 10.1016/j.jbi.2008.08.010.

252 [6] A. S. Iyer *et al.*, "Dried Blood Spots for Measuring Vibrio cholerae-specific Immune
253 Responses," *PLoS Negl Trop Dis*, vol. 12, no. 1, 2018, doi: 10.1371/journal.pntd.0006196.

254 [7] R. D. C. Team, "R: A language and Environment for statistical computing [Computer
255 software].," 2012.

256 [8] B. A. Muzembo, K. Kitahara, D. Mitra, A. Ohno, and S. I. Miyoshi, "Long-Term Kinetics
257 of Serological Antibodies against Vibrio cholerae Following a Clinical Cholera Case: A
258 Systematic Review and Meta-Analysis," *Int J Environ Res Public Health*, vol. 19, no. 12,
259 p. 7141, Jun. 2022, doi: 10.3390/IJERPH19127141/S1.

[9] C. M. Peak, A. L. Reilly, A. S. Azman, and C. O. Buckee, “Prolonging herd immunity to cholera via vaccination: Accounting for human mobility and waning vaccine effects,” *PLoS Negl Trop Dis*, vol. 12, no. 2, 2018, doi: 10.1371/journal.pntd.0006257.

[10] E. Briskin *et al.*, “Oral cholera vaccine coverage in Goma, Democratic Republic of the Congo, 2022, following 2019–2020 targeted preventative mass campaigns,” *Vaccine X*, vol. 20, p. 100555, Oct. 2024, doi: 10.1016/j.jvacx.2024.100555.

[11] M. S. Son and R. K. Taylor, “Vibriocidal Assays to Determine the Antibody Titer of Patient Sera Samples,” *Curr Protoc Microbiol*, vol. 23, no. 1, pp. 6A.3.1-6A.3.9, Nov. 2011, doi: 10.1002/9780471729259.MC06A03S23.


A.
10240
5120
1280
320
80
20
5
Titer (Log2 Scale)
7
30
90
180
360
Days Since Symptom Onset
Serotype Group
Inaba
Ogawa


B.
10240
5120
1280
320
80
20
5
Titer (Log2 Scale)
1
7
30
90
180
360
Days Since Symptom Onset
Age Group
Over 5
Under 5


Inaba & Ogawa Titer
Over 5
Under 5
Titer (Log2 Scale)
20480
10240
5120
1280
320
80
20
5
7
30
90
180
360
Days Since Symptom Onset